Calliditas Therapeutics (CALT) issues setanaxib patent update

Calliditas Therapeutics AB (Nasdaq: CALT) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer."

The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world, including a pending patent application in Europe.

"We are delighted that the product protection of setanaxib in the area of oncology is extended by way of this patent, and we look forward to expanding this to other geographies", said Renee Aguiar-Lucander, CEO.

Calliditas read out positive topline results of its Phase 2 head and neck cancer trial with setanaxib in May 2024. The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: [email protected]

The information was sent for publication, through the agency of the contact person set out above, on June 18, 2024 at 12:15 p.m. CET.

You May Also Be Interested In

• NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei
• WeTouch joins supply chain of major Japanese office equipment maker
• Arrow Electronics earns Microsoft Azure Virtual Desktop specialization